01608nam a2200241   4500001000700000010001500007090001100022100004100033101000800074200016600082210008300248215001700331330064000348606004900988606002401037606003001061606004101091606001701132606001901149710006801168955001101236995011901247384318  a9291681229  a384318  a20070531d2002       y0pory50      ba  aeng  aReport on the risk assessment of GHB in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction, EMCDDA  aLuxembourgcOffice for Official Publications of the European Communitiesd2002  a92 p.d21 cm  aForeword. Abbreviations. Introduction. report on the risk assessment of GBH in the framework of the joint action on new synthetic drugs. Europol-EMCDDA progress report on GHB in accordance with Article 3 of the joint action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs. Use of GHB as a medicinal product (EMEA). Review of the pharmacotoxicological data on gamma-hydroxybutyric acid (GHB). Sociological and criminological (Europol) evidence on the risks of GHB. Public health risks of GHB - epidemiological evidence. References. Participants in the risk-assessment process.  aPREVENÇÃO DA TOXICODEPENDÊNCIA9103892  aRELATÓRIO9410454  aDROGA SINTÉTICA9320915  aCOOPERAÇÃO INTERNACIONAL9229150  aOEDT9321506  aEMCDDA9324041  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION9351987  xOferta  104PJ_19_000000000000000_D_8952022-06-066PJ280909414210aPJcPJfPJ128090kPJ19.D.89n2022-06-06o0rMOxOferta